Inhibition of Thrombus Formation In Vivo by Novel Antiplatelet Agent

Ulla M. Marzec, Andrew B. Kelly, Stephen R. Hanson,
Andrew Lasslo, and Laurence A. Harker

The antithrombotic and antihemostatic effects of the novel antiplatelet compound, α,α'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide (GT-12), were investigated in a baboon model of platelet-dependent thrombosis under high flow conditions. In this model, segments of collagen-coated tubing and Dacron vascular graft were placed as thrombus-inducing extension devices in exteriorized femoral arteriovenous shunts. The deposition of ^{111}In-labeled platelets was measured for each thrombogenic segment throughout 1 hour by using gamma camera imaging. In addition, the ^{125}I-fibrin retained in the forming thrombus was measured. Intravenous infusion of GT-12 (100 μmol/kg, 63.3 mg/kg) over a 15-minute period before the insertion of the test segments prolonged the bleeding time from a baseline value of 4.4±0.4 min to 7.6±1.0 min ($p=0.036$) and inhibited platelet aggregation ex vivo induced by adenosine diphosphate (ED$_{50}$ 4.7±0.9 to 10.3±2.2 μM; $p<0.02$) and collagen (ED$_{50}$ 2.0±0.4 to 8.0±2.4 μg/ml; $p<0.05$). Deposition of platelets and fibrin was decreased in concert by 30% ($p<0.05$) for vascular grafts and possibly collagen segments at the end of the 60-minute observation period. We conclude that GT-12 is antithrombotic for Dacron graft-induced thrombus formation in vivo. (Arteriosclerosis 10:367–371, May/June 1990)

Platelets participate in the formation of thrombus under high flow conditions after vascular injury or exposure of blood to artificial surfaces.[1,2] Activation of platelets on these abnormal surfaces induces platelet recruitment of ambient platelets into forming thrombus by several different pathways, including: 1) adenosine diphosphate (ADP) released from platelet dense granules, 2) thromboxane A$_2$ (TxA$_2$) synthesized by platelets through metabolism of arachidonic acid, and 3) thrombin generated on the platelet surface.

The development of the antiplatelet agent, GT-12,[3-10] provided the opportunity to investigate its effect on thrombosis in a well-characterized baboon model.[11,12] In this model, segments of collagen-coated tubing and Dacron vascular graft are inserted as thrombogenic devices in an exteriorized arteriovenous (A-V) shunt circuit. Covalently bonded collagen-coated tubing and Dacron vascular grafts were selected as thrombogenic surfaces because of their clinical relevance, readily controlled blood flow, segment geometry, and highly reproducible thrombus formation and occlusion. GT-12 is thought to stabilize membrane complexes of the dense tubular system and other storage sites sequestering

calcium, thereby blocking the mobilization of additional Ca^{++} into the platelet cytosol.[3-10]

Methods

Normal male baboons (*Papio anubis/cynocephalus*) were used in these studies. All procedures were approved by the Institutional Animal Care and Use Committee in accordance with federal guidelines (Guide for the Care and Use of Laboratory Animals, 1986). The animals weighed 8 to 12 kg each and had been observed to be disease-free for at least 6 weeks before use. Each animal had a chronic A-V shunt surgically implanted between the femoral artery and vein. This chronic shunt did not detectably activate platelets or coagulation proteins.[12] For surgical procedures, the animals received atropine (0.4 mg/kg intramuscularly) as the pre-anesthesia and ketamine (10 mg/kg intramuscularly) as the inducing agent. Halothane was used as the anesthetic agent, and butorphenol (0.1 mg/kg twice daily for 2 days) was used for postoperative analgesia.

Segments of Dacron vascular grafts (U.S. Catheter, Billerica, MA; 4.0 mm i.d.) were rendered impervious to blood leakage by an external wrapping of Parafilm (American Can, Greenwich, CT) and were placed inside a 5 cm length of "heat-shrink" Teflon tubing as previously described.[11,12] These test segments were interposed between the arms of the permanent A-V shunt, and the blood flow rates were measured continuously with a Doppler ultrasound flowmeter (L&M Electronics, Daly City, CA). In all studies, the initial blood flow rates ranged between 160 and 240 ml/min, with a calculated wall shear rate of 424 to 637 sec^{-1}. In these studies, collagen-coated silicone rubber tubing was prepared in 2 cm

lengths as previously described[13] and was incorporated into the exteriorized A-V shunts distal to the segments of Dacron vascular grafts; the shear rates were calculated to be 844 to 1267 sec⁻¹ for the collagen segments.

Platelet counts and hematocrit determinations were performed on whole blood collected in 2 mg/ml disodium ethylenediaminetetraacetate (EDTA) with a J.T. Baker (Allentown, PA) Model 810 whole-blood analyzer. Mean whole-blood platelet counts were 405 000±52 000 platelets/μl; hematocrits averaged 34.6%. Bleeding time measurements were performed in duplicate on the shaved volar surface of the forearm by using the standard template method as previously described for studies in baboons.[14,15]

Autologous baboon blood platelets were labeled with ^{111}In-oxine as previously described.[11] In brief, whole blood (100 ml) was collected directly into plastic bags (TA-3, Fenwal Labs, Deerfield, IL) containing 20 ml of acid-citrate-dextrose anticoagulant (NIH formula A). The blood was centrifuged in the bag at 300 g for 10 minutes. The supernatant platelet-rich plasma (PRP) was transferred to a second bag, and the pH was adjusted to 6.5 by the addition of 0.15 M citric acid (0.1 ml/10 ml PRP). The red blood cell fraction was returned to the donor animal. The platelets were formed into a pellet by centrifugation of the PRP at 13 000 g for 15 minutes. The supernatant platelet-poor plasma (PPP) was completely decanted and discarded. To remove the residual plasma proteins, the bag containing the platelet pellet was carefully washed once by overlaying with 30 ml of Ringers citrate dextrose (RCD, pH 6.5), which was decanted and discarded. The pellet was then gently resuspended in 5.0 ml of RCD and was incubated for 30 minutes with 800 to 1000 μCi of ^{111}In-oxine (Amersham, Arlington Heights, IL). Contaminating red cells were removed by a final slow centrifugation at 200 g for 5 minutes. The labeling efficiencies averaged >90%. All the labeled platelets were re-infused, together with the previously separated red cells, for a total circulating platelet activity of 800 to 950 μCi.

Images of the Dacron grafts, including proximal and distal silicone rubber segments, were acquired with a Searle PhoGamma V scintillation camera and were stored on and analyzed by a Medical Data Systems A[3] computer (Medtronic, Ann Arbor, MI) interfaced with the camera. Immediately before imaging the vascular grafts, images were also acquired of 4.0 mm i.d. silicone rubber tubing filled with autologous blood and having the same luminal volume as the graft segment (blood standard). The activities of the standard and 5 cm graft segments were counted in the same region of interest as defined by image analysis software routines. Images were acquired at 5 minute intervals. Deposited ^{111}In-platelet activity calculated by subtracting the blood standard activity from all dynamic study images increased monotonically over the exposure period. The total number of platelets deposited after 1 hour (labeled plus unlabeled cells) was calculated by dividing the deposited platelet activity by the blood standard platelet activity, and multiplying by the volume of the blood standard and the circulating platelet

count (platelets/ml).[11,15] The results were expressed as platelets deposited/cm graft.

The concentration of fibrinogen was estimated spectrophotometrically by a modification of Jacobssen's method,[16] in which the optical density of thrombin-clottable protein was determined after collection on a glass rod and subsequent solution in 1% sodium dodecyl sulphate (SDS).

For quantifying the formation of fibrin on the collagen and vascular graft segments, we injected homologous ^{125}I-fibrinogen (approximately 5 μCi) intravenously 15 minutes before incorporation of the thrombogenic segments into the A-V shunts. Homologous fibrinogen was purified by β-alanine precipitation[17] and was labeled with ^{125}I by using the iodine monochloride method.[18,19] This preparation was >95% clottable in vitro. Additionally 95% of the ^{125}I activity was associated with the clot, thereby documenting that it was functionally equivalent to unlabeled fibrinogen. At the time of segment exposure, blood was collected in EDTA for the determination of both ^{125}I-fibrinogen activity and fibrinogen concentration, from which the specific activity was calculated. After a 1 hour exposure to flowing blood, the collagen and vascular graft segments were removed from the A-V shunt, were flushed with isotonic buffer, were placed in 10% buffered formalin fixative, and were stored at 4°C. After approximately 30 days, when the ^{111}In-activity had largely decayed, the ^{125}I-activity in each segment was counted and related to the standard and plasma ^{125}I-activity and plasma fibrinogen level at that time, using the formula:

deposited fibrin (mg)=

$$\frac{^{125}\text{I-activity in the segment (cpm)}}{\text{clottable plasma }^{125}\text{I-activity (cpm/ml)}}$$

$$\times \text{ plasma fibrinogen (mg/ml)}$$

The results were expressed as the total fibrin (mg/cm) contained in the thrombus associated with each segment.

The plasma levels of the platelet-specific α-granule proteins, PF4 and βTG, and fibrinopeptide A (FPA), a thrombin cleavage product of fibrinogen, were also determined by radioimmunoassay on blood samples collected and processed as described previously.[12]

Blood samples for platelet aggregation were collected in 0.1 vol of 3.2% sodium citrate before the start of the infusion, at the end of the infusion, and at the end of the imaging. PRP was prepared by centrifugation at 180 g for 10 minutes, and the concentration was adjusted to 250 000 platelets/μl with PPP, which was prepared by centrifugation at 13 000 g for 5 minutes. The maximal aggregation response to doses of ADP (Sigma Chemical, St. Louis, MO) and collagen (Hormon Chemie, Munich, FRG) bracketing the full range of reactivity was measured by using a dual-channel aggregometer (Chrono-Log, Havertown, PA). The concentration of agonist required to produce half-maximal aggregation of platelets, ED$_{50}$, was calculated for each agonist.[20]

GT-12 (100 μmol/kg [63.3 mg/kg]) was dissolved in 15 ml of sterile physiological saline, was then sterilized by filtration through a 0.22 μm syringe filter (Acrodisc, Gel-

Table 1. Effect of GT-12 on Platelet Function

Determination (n)	Baseline	15 min post GT-12 (100 μmol/kg)	60 min post GT-12 (100 μmol/kg)
Bleeding time (7)	4.4±0.4	7.6±1.0	5.1±0.6
		$p=0.036$†	$p>0.5$†
Platelet aggregation (7)			
ADP ED$_{50}$* (μM)	4.7±0.9	10.3±2.2	4.9±0.9
		$p<0.02$†	$p>0.5$†
Collagen ED$_{50}$* (7)	2.0±0.4	8.0±2.4	1.4±0.3
(μg/ml)		$p<0.05$†	$p>0.5$†

*That dose of agonist inducing half-maximal aggregation.
†Compared with baseline values.

man Sciences, Ann Arbor, MI), and was administered by continuous infusion by using a Harvard pump at the rate of 1 ml/min.

Statistical comparisons were made using Student's t test (two-tailed) for paired and unpaired sample groups when the data were normally distributed. The remaining results were compared by using Wilcoxon sign rank test.[21] All values are given as the means±1 SEM.

Results

Ex vivo platelet aggregation to ADP and collagen was significantly reduced after infusion of GT-12 (100 μmol/kg, 63.3 mg/kg). The ED$_{50}$ of ADP shifted from 4.7±0.9 μM to 10.3±2.2 μM ($p<0.02$), and for collagen from 2.0±0.4 μg/ml to 8.0±2.4 μg/ml ($p<0.05$). Sixty minutes after the infusion of GT-12, the ED$_{50}$ had returned to baseline for both agonists (Table 1).

The deposition of platelets and fibrin on Dacron graft in six animals treated with GT-12 was reduced in concert by 30% at 60 minutes compared to the matched control values (Table 2). Moreover, while one graft in the control group occluded at 50 minutes, all the grafts in the animals infused with GT-12 remained patent for the 60 minute observation period with no change in the blood flow. A time course for platelet deposition is displayed in Figure 1. A significant reduction in the number of deposited platelets was present at each time point. In two animals studied with collagen-coated segments, there was a reduction of fibrin and platelet deposition similar to results using the Dacron graft (Table 2).

The bleeding time was prolonged from a baseline of 4.4±0.4 minutes in the control group to 7.6±1.0 minutes by GT-12 at the end of the infusion period. There was no

Table 2. Effects of GT-12 on Thrombus Formation

Determination (n)	60 min post-placebo infusion	60 min post-GT-12 (100 μmol/kg)	p value
Platelet deposition (10^9 plat/cm)			
Dacron graft (6)	2.9±0.41	2.0±0.19	0.02
Collagen (2)	1.81, 1.33	0.69, 0.77	—
Fibrin deposition (mg/cm)			
Dacron graft (6)	1.47±0.22	1.0±0.22	0.025
Collagen (2)	0.13, 0.90	0.10, 0.40	—

Figure 1. Effect of GT-12 on platelet deposition. Thrombus formation in vivo was measured as the deposition of platelets onto a segment of Dacron vascular graft incorporated into an exteriorized femoral arteriovenous shunt during 60 minutes by using gamma camera imaging of autologous ^{111}In-platelets. A bolus intravenous infusion of GT-12 (100 μmol/kg) before placement of the graft reduced platelet deposition compared with saline-treated controls.

change in the fibrinogen concentrations or platelet counts from the control values of 2.86±0.38 mg/ml and 405 000±52 000 platelets/μl, respectively. The elevation of the platelet-specific α-granule proteins, PF4 and βTG, in plasma after the 1 hour exposure to the grafts, was less for the GT-12-treated animals (PF4 values decreased from 24.8±13.9 to 13.2±2.1, $p<0.04$, Table 3). The plasma FPA levels were significantly less in GT-12-treated animals compared to untreated controls (reduced from 10.6±4.3 pmol/l to 5.5±0.9 pmol/l, $p<0.05$).

Table 3. Effects of GT-12 on Blood Tests of Thrombosis

Determination (n)	Untreated	GT-12 (100 μmol/kg)	p value
Plasma PF4 (ng/ml)			
Baseline (6)	6.0±1.0	5.7±0.7	
Post-graft (6)	24.8±13.9	13.2±2.1	0.04
Plasma βTG (ng/ml)			
Baseline (6)	4.4±0.4	4.4±1.9	
Post-graft (6)	29.1±7.3	21.6±2.3	NS
Plasma FPA (pmol/l)			
Baseline (6)	2.2±0.4	2.8±0.5	
Post-graft (6)	10.6±4.3	5.5±0.9	0.05

Whereas baseline values were obtained before incorporation of the Dacron vascular grafts into the arteriovenous shunt, post-graft results were performed on samples drawn after the grafts had been in place for 60 minutes. P values relate to the post-graft data in treated vs. untreated animals.

PF4=platelet factor 4, βTG=β-thromboglobulin, FPA=fibrinopeptide A.

Discussion

The results obtained in these experiments clearly show reduced platelet reactivity and, concomitantly, decreased thrombus formation on Dacron vascular grafts after infusion of the carbamoylpiperidine congener, GT-12, into baboons compared with the control results (<0.05 in all cases). The findings for collagen-coated segments appeared to be similar. These in vivo effects were relatively short-lived after bolus infusion. There was a significant prolongation of the bleeding time which, however, normalized within minutes after the bolus infusion of GT-12. ADP- and collagen-induced platelet aggregation also completely normalized at the end of the 60 minute observation period. These findings are concordant with previous in vitro observations of inhibition of platelet aggregation and PF4 release.[22,23]

The results obtained in the thrombosis model used in this study are quantitative and reproducible and were obtained under physiological conditions of clearance and regulation of activities. Earlier work in this model with aspirin, dipyridamole, suloctidil, and heparin alone or in combination with aspirin or dipyridamole has demonstrated no detectable effect in the platelet deposition or thrombus formation.[11,12,20,24,25] On the other hand, ticlopidine, a potent global inhibitor of platelet function,[12,26] produces a thrombasthenic-like impairment in platelet hemostatic function with an intermediate effect on platelet deposition, similar to the effects of GT-12. More complete inhibition of platelet deposition on grafts has been reported with murine monoclonal antibodies directed against platelet receptor GPIIb/IIIa, which blocks the binding of fibrinogen,[15] and the synthetic covalent anti-thrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH$_2$Cl).[20]

Previous observations indicate that placement of the collagen segment distal to the Dacron vascular graft segment did not affect platelet or fibrin deposition on the collagen surface.[13] For example, in the present study, platelet deposition onto collagen in control studies was 1.81 and 1.33×10^9 plat/cm compared with 1.23±0.21 plat/cm for controls without associated segments of Dacron vascular graft.[13] Similarly, the fibrin deposition onto collagen segments in the present study was compared to previous experience without proximal segments of vascular graft.[13] Thus, the data suggest that proximal positioning of the segment of vascular graft did not affect the thrombogenicity of the collagen segment.

The compound, GT-12, or α,α'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene dihydrobromide, is one of a series of carbamoylpiperidine and nipecotoylpiperazine derivatives that inhibits human blood platelet aggregation.[4-8,22] The tertiary amines (structured around the ring nitrogens) in these compounds, identified as aggregation-inhibitory specific functions,[4,5] are subject to broad variances in protonation contingent upon the pH of their immediate vicinity and upon the specific compounds' pKa values. This very trait enables them in their specifically structured molecules[4-7,22] to assume the appropriate hydrophobic character for the penetration of the platelet membrane's lipid bilayer without interfering

subsequently with their transformation into corresponding cations.[4,5,6] Within this context, the penetrated amines in these surface-active molecules can be envisioned to generate their cationic species in quantities capable of interacting with and reducing the response sensitivity of anionic phospholipids.[27] These conclusions are supported by the findings of Sheetz and Singer[28,29] and Ferrel et al.,[30] despite the differing views regarding the putative mechanism of action for cationic amphipaths. The compounds are envisioned to stabilize membrane complexes of the dense tubular system and of other storage sites sequestering calcium in the platelets.[7,31] By enhancing the integrity of these membrane complexes, the compounds restrain Ca^{++} release into the platelet's cytosol[5-8] and impede activation of phospholipase A$_2$.[32] Moreover, by reducing the response sensitivity of anionic phospholipids,[27] the compounds render phosphatidyl-inositol-4,5-biphosphate (PIP$_2$) less susceptible to hydrolysis by phospholipase C and consequently suppress generation of inositol-1,4,5-trisphosphate (IP$_3$),[33] thought to be the principal trigger for the internal discharge of Ca^{++}.[34,35] Accordingly, the threshold for initiating or sustaining platelet aggregation becomes elevated.

GT-12 was selected for these studies from among a series of carbamoylpiperidine and nipecotoylpiperazine congeners because of its low acute toxicity in vivo (i.p.) in male ICR mice (LD$_{50}$=837 μM/kg) and its potent inhibition of ADP-induced human platelet aggregation in vitro (Ia$_{50}$, 11.4 μM).[10] Also, the compound blocks thrombus growth in human whole blood induced by collagen-coated glass under controlled flow (platelets per thrombus reduced by 86.7% at 50 μM concentrations).[8]

Dogs receiving GT-12 intravenously (150 μmol/kg, 94.9 mg/kg) showed substantial inhibition of ADP-induced platelet aggregation ex vivo.[9] The dose chosen for the present study was based on these preliminary data in dogs in which 50, 100, or 150 μmol/kg of the compound was injected intravenously over a 3 to 6 minute period[9]; side effects were noted with the highest dose consisting of salivation, perspiration, and muscle tremors. The infusion of 100 μM/kg in the baboons produced a detectable decrease in blood pressure of about 15 mm Hg in the awake animal lasting about 15 minutes, with no noticeable effect on the heart rate. Higher doses in two baboons were not well tolerated, and lesser doses in two other animals were judged to be ineffective.

The complex mechanisms involved in the formation of thrombus entail several different pathways of activation that interact to a variable extent. We have shown that the infusion of GT-12 in vivo inhibits several pathways of platelet activation and significantly reduces the deposition of platelets and fibrin during the formation of thrombus onto Dacron graft. It is our conclusion that GT-12, an inhibitor of platelet activation, affects platelet-dependent processes and has antithrombotic effects in vivo.

Acknowledgments

References

1. **Tirotto VT, Baumgartner HR.** Platelet-surface interactions. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis 2nd ed. Philadelphia: J.B. Lippincott, 1987:555–571

2. **Fitzgerald LA, Phillips DR.** Platelet membrane glycoproteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis 2nd ed. Philadelphia: J.B. Lippincott, 1987:572–593

3. **Lasslo A, Quintana RP, Dugdale M** (to the Research Corp., Tucson): Platelet aggregation-inhibitory agents. United States Patent 4,657,917; 14 April, 1987. Canadian Patent 1,220,140; 7 April, 1987

4. **Lasslo A, Quintana RP.** Interaction dynamics of blood platelets with medicinal agents and other chemical entities. In: Lasslo A, ed. Blood platelet function and medicinal chemistry. New York: Elsevier, 1984:229–315

5. **Lasslo A.** Blood platelet function, medicinal agents and other chemical entities. Fed Proc 1984;43:1382–1389

6. **Lasslo A, Quintana RP, Johnson RW, Naylor JL, Dugdale M.** Relationships between the chemical constitution of aggregation inhibitors and human blood platelet response profile. Biochim Biophys Acta 1984;772:84–92

7. **Lasslo A, White JG.** The effect of α,α'-bis[3-(N,N-diethylcarbamoyl)-piperidino]-p-xylene on human blood platelet structural physiology. Biochim Biophys Acta 1984;777:37–40

8. **Folie BJ, McIntire LV, Lasslo A.** Effects of a novel antiplatelet agent in mural thrombogenesis on collagen-coated glass. Blood 1988;72:1393–1400

9. **Lawrence WH, Gollamudi R, Dillingham EO, Carter-Burks G, Tisdelle PA, Lasslo A.** Preliminary in vivo studies on the platelet aggregation inhibitory activity of α,α'-bis[3-(N,N-diethylcarbamoyl)-piperidino]-p-xylene dihydrobromide in beagle dogs. J Pharm Sci 1988;77:464–465

10. **Lawrence WH, Tisdelle PA, Turner JE, et al.** Some novel inhibitors of platelet aggregation. Acute toxicity in mice and its relationship to in vitro activity and toxicity. Fundam Appl Toxicol 1988;10:499–505

11. **Hanson SR, Kotze HF, Savage B, Harker LA.** Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 1985;5:595–603

12. **Hanson SR, Harker LA.** Baboon models of acute arterial thrombosis. Thromb Haemost 1987;58:801–805

13. **Cadroy Y, Horbett TA, Hanson SR.** Discrimination between platelet and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J Lab Clin Med 1989;113:436–448

14. **Harker LA, Slichter SJ.** The bleeding time as a screen test for evaluation of platelet function. N Engl J Med 1972; 287:155–159

15. **Hanson SR, Pareti FI, Ruggeri ZM, et al.** Effects of monoclonal antibodies against platelet glycoprotein IIb/IIIa complex on thrombosis and haemostasis in the baboon. J Clin Invest 1988;81:149-158

16. **Jacobssen K.** Studies on the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest 1955;7(suppl 14):7–51

17. **Jakobsen E, Kierulf P.** A modified beta-alanine precipitation procedure to prepare fibrinogen free of antithrombin-III and plasminogen. Thromb Res 1973;3:145–159

18. **Horbett TA, Cheng CM, Ratner BD, Hoffman AS, Hanson SR.** The kinetics of baboon fibrinogen adsorption to polymers. In vitro and in vivo studies. J Biomed Mat Res 1986;20:739–772

19. **Helmkamp RW, Goodland RL, Bale WF, Spar IL, Mutschler LE.** High specific activity iodination of gammaglobulin with iodine-131 monochloride. Can Res 1960; 20:1495–1500

20. **Hanson SR, Harker LA.** Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988;85:3184–3188

21. **Zar JH.** Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall, 1974:124–126

22. **Lasslo A, Dillingham EO, Gollamudi R, Carter-Burks G.** Effects of novel aggregation inhibitors on serotonin uptake by human blood platelets. Biochim Biophys Acta 1987; 923:443–450

23. **Dillingham EO, Lasslo A, Carter-Burks G, Bond SE, Gollamudi R.** Relationships between chemical structure and inhibition of ADP-stimulated human thrombocyte release of serotonin and platelet factor 4. Biochim Biophys Acta 1989;990:128–132

24. **Bjornsson TD, Hanson SR, Harker LA.** Effective antiplatelet drug concentrations in experimental arterial thromboembolism. Thromb Res 1989;48:337–348

25. **Hanson SR, Harker LA, Bjornsson TD.** Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985; 75:1591–1599

26. **Hanson SR, Harker LA.** Studies of suloctidil in experimental thrombosis in baboons. Thromb Haemost 1985;53:423–427

27. **Quintana RP, Lasslo A, Greer LT.** Interaction of human blood platelet aggregation inhibitors with phospholipid films. Thromb Res 1981;24:379–395

28. **Sheetz MP, Singer SJ.** Biological membranes as bilayer couples. A molecular mechanism of drug-erythrocyte interactions. Proc Natl Acad Sci USA 1979;71:4457–4461

29. **Dombrose FA, Gitel SN, Zawalich K, Jackson CM.** The association of bovine prothrombus fragment I with phospholipid. J Biol Chem 1979;254:5027–5040

30. **Ferrel JE, Mitchell KT, Huestis WH.** Membrane bilayer balance and platelet shape: morphological and biochemical responses to amphipathic compounds. Biochim Biophys Acta 1988;939:223–237

31. **White JG.** The ultrastructure and regulatory mechanisms of blood platelets. In: Lasslo A, ed. Blood platelet function and medicinal chemistry. New York: Elsevier, 1984:15–59

32. **Kinlough-Rathbone RL, Mustard JF.** Endogenous mediators of platelet activation. In: McIntyre DE, Gordon JL, eds. Platelets in biology and pathology III. Amsterdam: Elsevier, 1987:239–267

33. **Chap H, Perret B, Plantavid M, Lachachichi F, Douste-Blazy L.** Topography of platelet membrane phospholipids. In: McIntyre DE, Gordon JL, eds. Platelets in biology and pathology III. Amsterdam: Elsevier, 1987:191–204

34. **Rink TJ.** Cytosolic calcium in platelet activation. Experientia 1988;44:97–100

35. **Magocsi M, Enyedi A, Sarkadi B, Gardos A.** Effects of phosphoinositides on calcium movements in human platelet membrane vesicles. Biochim Biophys Acta 1988;944: 202–212

Index Terms: antithrombotic therapy • antiplatelet agents • arterial thrombosis • baboon thrombosis model • carbamoyl piperidine congener

Inhibition of thrombus formation in vivo by novel antiplatelet agent.
U M Marzec, A B Kelly, S R Hanson, A Lasslo and L A Harker

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

http://atvb.ahajournals.org/content/10/3/367